Recognizing and exploiting differences between RNAi and small-molecule inhibitors
- 1 December 2007
- journal article
- research article
- Published by Springer Nature in Nature Chemical Biology
- Vol. 3 (12), 739-744
- https://doi.org/10.1038/nchembio1207-739
Abstract
The biology of RNA interference has greatly facilitated analysis of loss-of-function phenotypes, but correlating these phenotypes with small-molecule inhibition profiles is not always straightforward. We examine the rationale of comparing RNA interference to pharmacological intervention in chemical biology.Keywords
This publication has 26 references indexed in Scilit:
- Aurora kinases: shining lights on the therapeutic horizon?Oncogene, 2005
- Features of Selective Kinase InhibitorsChemistry & Biology, 2005
- Aurora-kinase inhibitors as anticancer agentsNature Reviews Cancer, 2004
- Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 HelixScience, 2004
- Aurora-A Kinase Maintains the Fidelity of Early and Late Mitotic Events in HeLa CellsJournal of Biological Chemistry, 2003
- Positive and Negative Roles of p85α and p85β Regulatory Subunits of Phosphoinositide 3-Kinase in Insulin SignalingJournal of Biological Chemistry, 2003
- The cellular geography of Aurora kinasesNature Reviews Molecular Cell Biology, 2003
- Identification and Prediction of Promiscuous Aggregating Inhibitors among Known DrugsJournal of Medicinal Chemistry, 2003
- Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochoresThe Journal of cell biology, 2003
- The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore–microtubule attachment and in maintaining the spindle assembly checkpointThe Journal of cell biology, 2003